Skip to main content

HomeResearchSplenin

Educational research tools — not medical advice.

CategoryRecovery
SafetyLow Risk
RegulatoryNot Evaluated
StatusResearch Only

Splenin

Spleen peptide bioregulator · Lys-Glu-Asp-Gly

CategoryRecovery
Half-lifeUnknown
Routesubcutaneous, intramuscular
RiskLow Risk
Providers1 listed#7 in Recovery

In brief

Splenin is a synthetic tripeptide (Lys-Glu-Asp, KED) classified as a Khavinson-class bioregulator peptide targeted at splenic and immune tissue, investigated for immunomodulatory and cytoprotective properties through…

Low Risk1 provider listed

About Splenin

Spleen-derived tetrapeptide bioregulator; normalizes leukocyte and platelet production; modulates splenic immune cell activity

Splenin is a synthetic tripeptide (Lys-Glu-Asp, KED) classified as a Khavinson-class bioregulator peptide targeted at splenic and immune tissue, investigated for immunomodulatory and cytoprotective properties through proposed gene expression regulatory mechanisms in lymphoid and hematopoietic cell populations. Like other short Khavinson bioregulator peptides, splenin is proposed to modulate gene expression in target immune cells via epigenetic mechanisms, with published research on the class demonstrating that ultrashort peptides can influence differentiation of stem and progenitor cells and regulate gene activity in aging tissues. Research on Khavinson-class ultrashort peptides has characterized neuroepigenetic mechanisms of action in neurodegeneration models and demonstrated peptide regulation of cell differentiation in stem cell preparations, providing the class-level mechanistic context within which splenin is proposed to act on immune tissue. Splenin has no FDA approval or regulatory approval in any major jurisdiction outside Russia; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.

Splenin Benefits & Research Areas

immune restorationblood cell productionsplenic function support

Research Signals

Population research notes

40s50+

These signals reflect research interest areas, not treatment indications.

Regulatory & Evidence

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.

Regulatory Status

Availability Status
Research Only
FDA Status
Not Evaluated

Russian peptide bioregulator from spleen (Khavinson Institute). Immunomodulatory. No FDA approval, no NDA or IND. Not on any FDA list. Research chemical in US only.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

2 sources cited · 2 moderate

2 Reviews

  • Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease

    International Journal of Molecular Sciences · 2022

    This review examines proposed epigenetic mechanisms by which ultrashort peptides including Khavinson tissue-specific peptides such as splenin may exert neuroprotective effects through interactions with histone proteins, DNA regulatory elements, and non-coding RNAs, offering a hypothesis for peptide-based modulation of neuroinflammatory and neurodegenerative processes.

    ReviewModeratePMID 35457077
  • Peptide Regulation of Cell Differentiation

    Stem Cell Reviews and Reports · 2020

    This review summarizes evidence that short peptides of 2 to 7 amino acids regulate differentiation of immune, neural, epithelial, and stem cells by modulating histone accessibility, DNA methylation, and signaling pathway activation, providing a mechanistic framework for tissue-specific differentiation activity attributed to Khavinson peptides including splenin.

    ReviewModeratePMID 31808038

Splenin Side Effects & Safety Considerations

Low Risk

Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.

Reported contraindications & considerations

None Well-Established

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Where to Buy Splenin — Providers & Availability

1 provider
1 in stock

Stay updated on verified Splenin providers

New verified providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Questions to Ask Your Provider

Frequently Asked Questions — Splenin

Splenin is a synthetic tripeptide (Lys-Glu-Asp, KED) classified as a Khavinson-class bioregulator peptide targeted at splenic and immune tissue, investigated for immunomodulatory and cytoprotective properties through proposed gene expression regulatory mechanisms in lymphoid and hematopoietic cell populations. Like other short Khavinson bioregulator peptides, splenin is proposed to modulate gene expression in target immune cells via epigenetic mechanisms, with published research on the class demonstrating that ultrashort peptides can influence differentiation of stem and progenitor cells and regulate gene activity in aging tissues.

immune restoration, blood cell production, splenic function support.

Research on Splenin primarily documents effects related to immune restoration and blood cell production and splenic function support. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for Splenin include none well-established. This is educational information only — consult a qualified healthcare professional before use.

1 provider in the directory currently offers Splenin.

This review examines proposed epigenetic mechanisms by which ultrashort peptides including Khavinson tissue-specific peptides such as splenin may exert neuroprotective effects through interactions with histone proteins, DNA regulatory elements, and non-coding RNAs, offering a hypothesis for peptide-based modulation of neuroinflammatory and neurodegenerative processes.

Last updated

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.